%0 Journal Article %J Blood//Blood %D 2013 %T New autoimmune diseases after cord blood transplantation: a retrospective study of EUROCORD and the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation. %A Daikeler, Thomas %A Labopin, Myriam %A Ruggeri, Annalisa %A Crotta, Alessandro %A Abinun, Mario %A Hussein, Ayad Ahmed %A Carlson, Kristina %A Cornillon, Jerome %A Diez-Martin, Jose L %A Gandemer, Virginie %A Faraci, Maura %A Lindemans, Caroline %A O'Meara, Anne %A Mialou, Valerie %A Renard, Marleen %A Sedlacek, Petr %A Sirvent, Anne %A Socie, Gerard %A Sora, Federica %A Varotto, Stefania %A Sanz, Jaime %A Voswinkel, Jan %A Vora, Ajay %A Yesilipek, M Akif %A Herr, Andree-Laure %A Gluckman, Eliane %A Farge, Dominique %A Rocha, Vanderson %K *Autoimmune Diseases/et [Etiology] %K *Cord Blood Stem Cell Transplantation/ae [Adverse Effects] %K *Outcome Assessment (Health Care)/sn [Statistics & Numerical Data] %K *Risk Assessment/sn [Statistics & Numerical Data] %K Adolescent %K Adult %K Aged %K Antibodies, Monoclonal, Murine-Derived/tu [Therapeutic Use] %K Autoimmune Diseases/dt [Drug Therapy] %K Child %K Child, Preschool %K Cyclosporine/tu [Therapeutic Use] %K Female %K Follow-Up Studies %K Humans %K Immunologic Factors/tu [Therapeutic Use] %K Immunosuppressive Agents/tu [Therapeutic Use] %K Infant %K Male %K Middle Aged %K Multivariate Analysis %K Outcome Assessment (Health Care)/mt [Methods] %K Retrospective Studies %K Risk Assessment/mt [Methods] %K Risk Factors %K Steroids/tu [Therapeutic Use] %K Survival Analysis %K Young Adult %X To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative incidence of ADs after CBT was 5.0% +/- 1% at 1 year and 6.6% +/- 1% at 5 years. Patients developing ADs were younger and had more nonmalignant diseases (P < .001). ADs target hematopoietic (autoimmune hemolytic anemia, n = 20; Evans syndrome, n = 9; autoimmune thrombocytopenia, n = 11; and immune neutropenia, n = 1) and other tissues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n 1; membranous glomerulonephritis, n = 2; rheumatoid arthritis, n = 1; ulcerative colitis, n = 1; and systemic lupus erythematosus, n = 1). Four patients developed 2 ADs (3 cases of immune thrombocytopenia followed by autoimmune hemolytic anemia and 1 Evans syndrome with rheumatoid arthritis). By multivariate analysis, the main risk factor for developing an AD was nonmalignant disease as an indication for CBT (P = .0001). Hematologic ADs were most often treated with steroids, rituximab, and cyclosporine. With a median follow-up of 26 months (range, 2-91), 6 of 52 patients died as a consequence of ADs. We conclude that CBT may be followed by potentially life-threatening, mainly hematologic ADs. %B Blood//Blood %I Daikeler,Thomas. Eurocord, Hopital Saint Louis Assistance Publique des Hopitaux de Paris (AP-HP), University Paris VII, Paris, France. tdaikeler@uhbs.ch %C United States %V 121 %P 1059 - 64 %8 2013 %@ 1528-0020 %G eng %N 6 %< http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=medl&NEWS=N&AN=23247725